BIODESIX, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M | $45.6M | $24.6M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $12.0M | $9.6M | $10.0M | $13.1M | $12.8M | $10.8M | $10.5M |
| SG&A Expense | $87.5M | $80.5M | $67.4M | $61.5M | $50.5M | $34.9M | $30.6M |
| Operating Income | $-27.9M | $-34.5M | $-41.3M | $-50.6M | $-40.9M | $-22.9M | $-26.7M |
| Operating Margin | -31.5% | -48.4% | -84.2% | -132.4% | -75.1% | -50.3% | -108.9% |
| Interest Expense | $7.7M | $8.3M | $9.5M | $8.1M | $4.5M | $7.6M | $3.0M |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-35.3M | $-42.9M | $-52.1M | $-65.4M | $-43.2M | $-65.4M | $-30.7M |
| Net Margin | -39.8% | -60.2% | -106.2% | -171.3% | -79.2% | -143.7% | -125.1% |
| EPS (Basic) | $-4.67 | $-6.64 | $-0.64 | $-1.55 | $-1.58 | $-6.48 | $-126.97 |
| EPS (Diluted) | $-4.67 | $-6.64 | $-0.64 | $-1.55 | $-1.58 | $-6.48 | $-126.97 |
| Shares Outstanding (Basic) | 7.6M | 6.5M | 82.1M | 42.1M | 27.4M | 26.6M | 254.9K |
| Shares Outstanding (Diluted) | 7.6M | 6.5M | 82.1M | 42.1M | 27.4M | 26.6M | 254.9K |
| Dividends Per Share | — | — | — | — | — | — | — |